Intrathecal Baclofen for Spastic Hypertonia From Stroke

Open Access
Publisher Website
Google Scholar
Abstract
Background and Purpose — We sought to determine whether continuous intrathecal delivery of baclofen can effectively decrease spastic hypertonia due to stroke. Methods — Stroke patients with >6 months of intractable spasticity were screened via a randomized, double-blind, placebo-controlled crossover design of either intrathecal normal saline or 50 μg baclofen. Those who dropped an average of 2 points in either their affected lower extremity side Ashworth or Penn spasm frequency scores were then offered computer-controlled pump implantation for continuous ITB and followed prospectively for up to 12 months. Results — In 21 stroke patients 6 hours after the active drug bolus, the average (±SD) lower extremity Ashworth score on the affected extremities decreased from 3.3±1.2 to 1.4±0.7 ( P P =0.0224), and reflex score from 2.1±1.2 to 0.1±0.5 ( P P P =0.1544), and reflex score from 2.1±0.9 to 1.2±0.9 ( P =0.0004). All active drug scores were statistically different from placebo scores at 6 hours ( P P P =0.4282), and the reflex score decreased from 2.4±1.3 to 1.0±1.3 ( P P P =0.8685), and the reflex score decreased from 2.4±0.8 to 1.5±1.2 ( P =0.3337). The average continuous ITB dose required to attain these effects was 268 μg/d. Conclusions — Intrathecal infusion of baclofen is capable of maintaining a reduction in the spastic hypertonia resulting from stroke.

This publication has 26 references indexed in Scilit: